Tandem Diabetes Care Inc (TNDM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Tandem Diabetes Care Inc (TNDM) has a cash flow conversion efficiency ratio of 0.063x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($9.79 Million) by net assets ($155.17 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Tandem Diabetes Care Inc - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Tandem Diabetes Care Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Tandem Diabetes Care Inc balance sheet liabilities for a breakdown of total debt and financial obligations.
Tandem Diabetes Care Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tandem Diabetes Care Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Chengdu Fusen Noble-House Industrial Co Ltd
SHE:002818
|
0.067x |
|
Gs Retail
KO:007070
|
0.104x |
|
PDF Solutions Inc
NASDAQ:PDFS
|
0.012x |
|
Guangzhou Risong Intelligent Technology Holding Co Ltd
SHG:688090
|
0.050x |
|
Centuria Industrial REIT
AU:CIP
|
0.020x |
|
Thangamayil Jewellery Limited
NSE:THANGAMAYL
|
-0.093x |
|
Ecovyst Inc
NYSE:ECVT
|
0.091x |
|
Winmark Corporation
NASDAQ:WINA
|
-0.465x |
Annual Cash Flow Conversion Efficiency for Tandem Diabetes Care Inc (2011–2025)
The table below shows the annual cash flow conversion efficiency of Tandem Diabetes Care Inc from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see Tandem Diabetes Care Inc (TNDM) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $155.17 Million | $-9.72 Million | -0.063x | -168.04% |
| 2024-12-31 | $263.10 Million | $24.23 Million | 0.092x | +190.78% |
| 2023-12-31 | $313.63 Million | $-31.81 Million | -0.101x | -188.42% |
| 2022-12-31 | $439.95 Million | $50.46 Million | 0.115x | -55.39% |
| 2021-12-31 | $433.11 Million | $111.36 Million | 0.257x | +281.78% |
| 2020-12-31 | $366.31 Million | $24.67 Million | 0.067x | -68.67% |
| 2019-12-31 | $194.98 Million | $41.91 Million | 0.215x | +439.16% |
| 2018-12-31 | $131.28 Million | $-8.32 Million | -0.063x | -102.79% |
| 2017-12-31 | $-29.15 Million | $-66.14 Million | 2.269x | -78.02% |
| 2016-12-31 | $-5.93 Million | $-61.17 Million | 10.321x | +1214.73% |
| 2015-12-31 | $63.47 Million | $-58.76 Million | -0.926x | +17.68% |
| 2014-12-31 | $54.57 Million | $-61.38 Million | -1.125x | -172.10% |
| 2013-12-31 | $115.54 Million | $-47.76 Million | -0.413x | -230.97% |
| 2012-12-31 | $-106.05 Million | $-33.47 Million | 0.316x | +4.43% |
| 2011-12-31 | $-71.29 Million | $-21.55 Million | 0.302x | -- |
About Tandem Diabetes Care Inc
Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. It's flagship products are the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system. The company also sells single-use products, including cartridges for storing and delivering insulin, and … Read more